Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Cancer Immunology, Immunotherapy : CII|November 30, 2006
In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccinesReshma Singh, Yvonne PatersonScience (New York, N.Y.)|June 12, 2010
Defective cross-presentation of viral antigens in GILT-free miceReshma Singh, Peter CresswellCancer Research|August 4, 2006
Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancerReshma Singh, Yvonne PatersonExpert Review of Vaccines|September 23, 2006
Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapyReshma Singh, Yvonne PatersonHuman Vaccines|March 23, 2011
Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinicReshma Singh, Anu WallechaCancer Research|March 3, 2007
Immunoediting sculpts tumor epitopes during immunotherapyReshma Singh, Yvonne PatersonJournal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironmentAnu Wallecha, Reshma Singh, Inga MalininaNature|September 26, 2008
GILT is a critical host factor for Listeria monocytogenes infectionReshma Singh, Amanda Jamieson, Peter CresswellJournal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouseReshma Singh, Mary E Dominiecki, Elizabeth M Jaffee, et al.Journal of Oncology|April 7, 2012
Lm-LLO-Based Immunotherapies and HPV-Associated DiseaseAnu Wallecha, Chris French, Robert Petit, et al.Pageof 2